Lizandra Gutierrez
Nurse Practitioner · Syracuse, NYNPI 1649735010
Payments from drug & device makers
Across 107 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$626
- Genentech USA, Inc.$434
- Pfizer$193
- Lundbeck LLC$124
- TG Therapeutics, Inc.$95
- Jazz Pharmaceuticals Inc.$93
- plus $524 from 13 others
What the payments were for
- Food & beverage$2,089100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $626 |
| Genentech USA, Inc. | 22 | $434 |
| Pfizer | 8 | $193 |
| Lundbeck LLC | 6 | $124 |
| TG Therapeutics, Inc. | 5 | $95 |
| Jazz Pharmaceuticals Inc. | 3 | $93 |
| Averitas Pharma Inc. | 3 | $75 |
| SK Life Science, Inc. | 3 | $60 |
| Lilly USA, LLC | 3 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $58 |
| Argenx US, Inc. | 3 | $56 |
| Acadia Pharmaceuticals Inc | 2 | $44 |
| Ipsen Biopharmaceuticals, Inc | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| UCB, Inc. | 1 | $24 |
| Cycle Pharmaceuticals Inc | 1 | $21 |
| Eisai Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
How this compares
$2,089 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 40 | $56,214 |
| UbrelvyUbrogepant | 33 | $51,827 |
| Aimovig AutoinjectorErenumab-Aooe | 39 | $28,604 |
| BriviactBrivaracetam | 12 | $19,040 |
| QuliptaAtogepant | 12 | $13,651 |
| Oxcarbazepine | 25 | $3,774 |
| Divalproex Sodium | 19 | $1,692 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 11 | $1,628 |
| Divalproex Sodium ErDivalproex Sodium | 26 | $1,618 |
| Gabapentin | 82 | $1,378 |
| Levetiracetam | 36 | $1,358 |
| Memantine Hcl | 65 | $1,309 |
| Zonisamide | 15 | $1,236 |
| Rasagiline Mesylate | 11 | $1,047 |
| Topiramate | 100 | $1,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $626 | $65,47945 claims |
| PfizerNurtec Odt | $193 | $56,21440 claims |
| UCB, Inc.Briviact | $24 | $19,04012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Syracuse
- Michelle DartSyracuse$95K
- Anne DowSyracuse$15K
- Patricia McGoldrickNew York$202K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.